Please login to the form below
biologic
This page shows the latest biologic news and features for those working in and with pharma, biotech and healthcare.
NHS England sees off AbbVie's Hep C legal challenge
It says it believes patients who are stable on their biologic medicine should not be switched to another product for ‘non medical reasons’ – but had to also ensure that its Humira
Latest news
-
Evenity back on track with FDA panel blessing in osteoporosis
blockbuster osteoporosis biologic Prolia (denosumab) which is in the last few years of its patent life.
-
AstraZeneca unveils reorg, hires controversial José Baselga as cancer chief
Mene Pangalos will be the leader of a new unified Research and Development unit for BioPharmaceuticals, ending the split between MedImmune biologics research and AstraZeneca’s small molecule research division.
-
Merck’s backing of NGM Bio yields NASH drug deal
into its biologic drug discovery expertise.
-
Drug pricing is pharma’s top concern in 2019
Views were mixed on other factors that would have the greatest positive impact, with the rise of China as a competitor, vertical integration and patent expiry of biologics all expected to
-
Orphan drugs dominate FDA's record-breaking year
The FDA approved 46 drugs in 2017, which had itself matched a 2015 record, but last year saw a further surge in new approvals in new chemical entities and new biologic ... s IDH1 inhibitor Tibsovo (ivosidenib) for acute myeloid leukaemia (AML),
More from news
Approximately 18 fully matching, plus 514 partially matching documents found.
Latest Intelligence
-
Is China ready for a pharmaceutical gold rush?
On top of that, several local firms including Junshi Biosciences, Innovent Biologics and Hengrui Medicine, are developing their own PD-1 I-O treatments that are expected to hit the market ... Innovent Biologics Inc raised HK$3.3bn ($421m) at a valuation
-
AstraZeneca’s oncology renaissance
Imfinzi, competing in the hypercompetitive world of immuno-oncology, was developed by MedImmune, the company’s US-based biologics research division, while the two small molecule drugs were developed in the ... The third area is immuno-oncology (IO)
-
Deal Watch October 2018
non‐biologic product post‐patent loss, highlighting the benefits of biologics in the long term and the complexities of developing and manufacturing them. ... $307m. Samsung Bioepis/. Merck &Co. Lusduna Nexvue follow‐on biologic. Termination. $155m.
-
Nudge-nudge, think-think
The power of achieving the triad of capability, opportunity and peer endorsement is evidenced by a recent study into how to avoid retrograde outcomes when switching patients from biologics to biosimilars.
-
Making Europe a leader in bioscience: boosting trust and opening minds
New disruptive innovation is changing the way we create value in healthcare: big data, artificial intelligence, the growing role of patients, the discovery of new materials and biologics, gene, cell and
More from intelligence
Approximately 2 fully matching, plus 72 partially matching documents found.
Latest appointments
-
Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO
Bahija has more than 25 years of international leadership experience within the pharmaceutical industry, and joins Immunocore from AstraZeneca, where she has served as President of MedImmune, its global biologics research ... A champion for science and
-
BMS appoints new commercial leader, Davies joins Eisai and more
Commenting on her appointment, Schuermans said: “Sobi has unique capabilities, a heritage in biologics manufacturing, development and supply, and a very exciting future within the rare disease space.
-
Industry appointments
Most recently, Hassan built the oncology-focused biology, preclinical and biomarker units for Immunocore, overseeing early development and the first-in-human trial of a TCR based biologic targeting a melanoma
-
Nabriva Therapeutics appoints chief medical officer
medical affairs for small molecules and biologics.
-
Ipsen appoints Aidan Murphy as EVP, technical operations
He is promoted from senior VP biologics development and manufacturing. Ipsen has added to its executive leadership team in the form of Aidan Murphy, who becomes the biopharma’s executive vice ... being senior vice president biologics development and
More from appointments
Approximately 7 fully matching, plus 46 partially matching documents found.
Latest from PMHub
-
Protein Expression Market Trends, Regulations And Competitive Landscape Outlook to 2025
The expanding biologics and proteomics market will increase the demand for more pure forms of proteins from fields such as biotechnology, drug researches etc. ... Other major factors responsible for this regions’ fast growth are rapidly increasing
-
Pharma and Healthcare Social Media Marketing Intelligence Report Offers Growth Prospects
The involvement of regulatory authorities in drafting and issuing guidance for use of interactive media for drugs and biologics proves to be instrumental in deciding the importance of social media marketing ... requirements for post marketing submissions
-
Leukemia Therapeutics Treatment Market Is Expected To Generate Huge Profits by 2015 - 2025
and biologic therapies. ... biologic therapies.
-
Chromatography Instrumentation Market to Witness Steady Growth During the Forecast Period 2015-2025
Further, augmented research and development activities of drugs and biologics and increasing number of conferences on chromatography are some of the key drivers of this industry.
-
Ultrasonic Homogenizers Market Global Industry Analysis, Trends and Forecast, 2017-2027
KG Hielscher Ultrasonics GmbH, BioLogics Inc. OMNI International, Pro Scientific INC., Sonic Corporation, Topas GmbH, etc.
More from PMHub
Approximately 7 fully matching, plus 41 partially matching documents found.
Featured jobs
-
Business Director
-
Competitive Salary Offered
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
-
Account Director
-
Competitive Salary Offered
-
Senior Medical Writer
-
Salary TBC
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
- Global Business Development Director – Health Education
-
excellent commission
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
-
Medical Writer
-
Salary TBC
- Senior Account Director development role to Business Director, H...
-
Excellent package
-
Associate Director
-
£75, 000-90, 000
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
- Account Manager / Senior Account Manager
-
35, 000-40, 000
-
Account Manager / Account Director
-
Competative
-
Senior Account Manager
-
Competitive Salary Offered
-
Account Director, Medical Education
-
Salary TBC
Subscribe to our email news alerts
- Meet Porterhouse Medical at the ISMPP EU meeting 2019 in London 22 - 23 January
- Immunomedics craters after FDA rejects breast cancer ADC
- UK businesses leaning towards second Brexit vote
- NHS England sees off AbbVie's Hep C legal challenge
- China’s clinical trial shake-up
- Europe closer to biosimilar rule change, despite fierce resistance from pharma
PMHub
GCI Health
GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...
Latest intelligence
- China’s clinical trial shake-up
- As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
- Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
- Healthcare leaders in the European Union should begin preparing for a breakthrough now...
- The UK’s new five-year pricing agreement
- Pharma has agreed to capped growth again - in exchange for uptake promises...
Quick links
Infographics
